Mochizuki Yuichi, Ishikawa Tatsuya, Aihara Yasuo, Yamaguchi Koji, Kawamata Takakazu
Department of Neurosurgery, Tokyo Women's Medical University, Tokyo, Japan.
Department of Neurosurgery, Tokyo Women's Medical University, Tokyo, Japan.
J Stroke Cerebrovasc Dis. 2019 Mar;28(3):665-671. doi: 10.1016/j.jstrokecerebrovasdis.2018.11.010. Epub 2018 Nov 30.
Antiplatelet drugs are administered before and after carotid endarterectomies (CEAs), but their efficacy for preventing restenosis remains unclear. Hence, this study aimed to identify associations between postoperative restenosis and platelet aggregability in CEA patients.
Thirty-six consecutive CEA patients treated at Tokyo Women's Medical University from May 2013 to March 2015 were included in this retrospective study. Restenosis was defined as a stenosis ratio greater than or equal to 50% per the European Carotid Surgery Trial criteria or peak systolic velocity of 150 cm/s on carotid ultrasound. Platelet aggregability was measured turbidimetrically using a light-transmission platelet aggregometer and analyzed in terms of aggregation profiles for 2 concentrations of collagen used to induce aggregation (.25 and 2.0 μg/mL). Patients were automatically divided into 9 classes (Class 1-9, from the lowest to the highest aggregability) using a software program according to area under their platelet aggregation curves. Each class was subdivided into 10 further gradations for a total of 90 possible scores (10-99) using a software program. Patients were divided into high- and low-platelet aggregability score groups (cut-off = 49).
Data were analyzed for 36 of the 99 patients. Restenosis was observed in 10 (28%) patients. Restenosis incidence was significantly higher in patients with high-platelet aggregability score than in those with low-platelet aggregability score (50.0% [7/14] versus 13.6% [3 of 22]: P = .0176, odds ratio = 6.34, 95% CI: 1.27-31.57).
Platelet aggregability is a useful metric for predicting and preventing restenosis after CEA. It has potential as an indicator for determining the optimal dose of antiplatelet drugs.
抗血小板药物在颈动脉内膜切除术(CEA)前后均有使用,但其预防再狭窄的疗效仍不明确。因此,本研究旨在确定CEA患者术后再狭窄与血小板聚集性之间的关联。
本回顾性研究纳入了2013年5月至2015年3月在东京女子医科大学接受治疗的36例连续CEA患者。根据欧洲颈动脉外科试验标准,再狭窄定义为狭窄率大于或等于50%,或颈动脉超声显示收缩期峰值流速为150 cm/s。使用透光血小板聚集仪通过比浊法测量血小板聚集性,并根据用于诱导聚集的2种胶原蛋白浓度(0.25和2.0μg/mL)的聚集曲线进行分析。使用软件程序根据血小板聚集曲线下面积将患者自动分为9类(1-9类,从最低聚集性到最高聚集性)。使用软件程序将每类再细分为10个进一步的等级,总共90个可能的分数(10-99)。患者分为高血小板聚集性评分组和低血小板聚集性评分组(临界值=49)。
对99例患者中的36例进行了数据分析。10例(28%)患者出现再狭窄。高血小板聚集性评分患者的再狭窄发生率显著高于低血小板聚集性评分患者(50.0%[7/14]对13.6%[22例中的3例]:P = 0.0176,优势比=6.34,95%CI:1.27-31.57)。
血小板聚集性是预测和预防CEA术后再狭窄的有用指标。它有潜力作为确定抗血小板药物最佳剂量的指标。